Revelation Biosciences, Inc.
REVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001810560
No open-market purchases or sales by Revelation Biosciences, Inc. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $313.2K in total; no superinvestor holds it.
Other share classesREVBW
Q2 2023 vs. Q1 2023
How the institutions holding Revelation Biosciences, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 11 | 10 | −1 |
| Shares | 806.1K | 805.3K | −843 (−0.1%) |
| Value | $1.05M | $758.7K | −$289.1K (−27.6%) |
New holders (4)
Institutions that held Revelation Biosciences, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 66,972 | $63.0K | 0.00% |
| HRT Financial LP | 18,484 | $17.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,102 | $1.04K | 0.00% |
| Royal Bank of Canada | 100 | $0 | 0.00% |
Sold out (5)
Institutions that held Revelation Biosciences, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Anson Funds Management LP | 213,509 | $277.6K |
| Hudson Bay Capital Management LP | 109,520 | $142.4K |
| Altium Capital Management LP | 37,198 | $48.4K |
| CVI Holdings, LLC | 33,204 | $43.2K |
| UBS Group AG | 1,362 | $1.77K |